Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
BETHESDA, Md., May 16, 2017 -- India Globalization Capital Inc. (NYSE MKT:IGC) announces that Craig Cheifetz, M.D. has joined the company as an advisor to provide guidance on clinical trials, biotechnology, neuroscience, immunology and microbiology.
Dr. Cheifetz is currently Regional Dean at Virginia Commonwealth University Inova Fairfax Campus and is the Medical Director of Inova VIP 360 (Northern Virginia's premier Concierge Medicine Program). Dr. Cheifetz received his M.D. from the State University of New York College at Buffalo and trained in Internal Medicine at Georgetown University. From 2011 to 2013, he served as the National GRMC Chairman.
“I welcome Dr. Cheifetz to the IGC advisory team and look forward to his contributions as we move forward in developing cannabis-based, combination therapies. We remain committed to accelerating our initiatives and building a robust portfolio of compounds to address large market conditions,” states Ram Mukunda, CEO of IGC.
About IGC
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.
For more information visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see forward-looking statements as discussed in detail in IGC's Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports filed with the U.S. Securities and Exchange Commission.
Contact Info: Claudia Grimaldi 301-983-0998
